Home › Funds › TCV Trust & Wealth Management, Inc. › ABT
TCV Trust & Wealth Management, Inc. position in ABT
ABBOTT LABORATORIES · Health Care
TCV Trust & Wealth Management, Inc. reported holding 129,001 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$12.7M, representing 0.99% of its reported portfolio and ranking #37 among its reported holdings. TCV Trust & Wealth Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR
How TCV Trust & Wealth Management, Inc.'s ABT position evolved
TCV Trust & Wealth Management, Inc. first disclosed a stake in ABT in Q3 2023 at 119,355 shares (US$11.6M). The position peaked in Q2 2025 at 122,074 shares, worth US$16.6M. Across 13 filings, TCV Trust & Wealth Management, Inc. increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 129,001 shares valued at US$12.7M — an increase of 3,284 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 119.36K | $11.56M | New |
| Q4 2023 | 120.15K | $13.23M | Add |
| Q1 2024 | 118.01K | $13.41M | Reduce |
| Q2 2024 | 120.05K | $12.47M | Add |
| Q3 2024 | 119.40K | $13.61M | Reduce |
| Q4 2024 | 121.86K | $13.78M | Add |
| Q1 2025 | 123.53K | $16.39M | Add |
| Q2 2025 | 122.07K | $16.60M | Reduce |
| Q3 2025 | 119.12K | $15.96M | Reduce |
| Q4 2025 | 123.77K | $15.51M | Add |
| Q1 2026 | 122.52K | $12.58M | Reduce |
| Q2 2026 | 125.72K | $11.41M | Add |
| Q3 2026 | 129.00K | $12.75M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on TCV Trust & Wealth Management, Inc.
FAQ
How long has TCV Trust & Wealth Management, Inc. held ABT?
TCV Trust & Wealth Management, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is TCV Trust & Wealth Management, Inc.'s current position in ABT?
As of Q3 2026, TCV Trust & Wealth Management, Inc. holds 129.00K shares of ABT (ABBOTT LABORATORIES), valued at $12.75M, representing 0.99% of its reported portfolio and ranking #37.
Has TCV Trust & Wealth Management, Inc. been buying or selling ABT?
In the latest 13F filing (Q3 2026), TCV Trust & Wealth Management, Inc. increased its position in ABT. The position peaked in Q2 2025 at 122.07K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.